Search

Search bills, members, committees and pages...

Sign In

H.R. 7877

U.S. House•Introduced

Summary

H.R. 7877, the Shane DiGiovanna Act, was introduced in the House on Mar 9, 2026 by Rep. Greg Landsman (D) with 5 co-sponsors. It last saw action on Mar 17, 2026: Sponsor introductory remarks on measure. (CR H2535).

Record

Text

H.R. 7877 has 5 co-sponsors.

hb7877/introduced-in-house.txt
119 HR 7877 IH: Shane DiGiovanna Act
 U.S. House of Representatives
 2026-03-09
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  2d Session  H. R. 7877  IN THE HOUSE OF REPRESENTATIVES   March 9, 2026   Mr. Landsman  introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
1.
Short title
This Act may be cited as the   Shane DiGiovanna Act  .
2.
Demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program
(a)
In general
Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the  Secretary ) shall conduct a 2-year demonstration program under which items and services specified in subsection (b) furnished for the treatment of epidermolysis bullosa are required to be included as medical assistance under a State plan (or waiver of such plan) under title XIX of the Social Security Act ( 42 U.S.C. 1396 et seq. ) for individuals described in section 1902(a)(10)(A)(i) of such Act ( 42 U.S.C. 1396a(a)(10)(A)(i) ).
(b)
Specified items and services
For purposes of subsection (a), the items and services specified in this subsection are over-the-counter antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, and necessary wound care supplies, including wound care dressings (inclusive of primary and secondary dressings), gauze, and bandage retainers.
(c)
Scope of demonstration
The Secretary shall conduct the demonstration program described in subsection (a) on a nationwide basis.
(d)
Study
Not later than 1 year after the end of the demonstration program described in subsection (a), the Secretary shall submit to Congress a report on such program. Such report shall include the following:
(1)
An evaluation of the effect of such program on expenditures for treatment of individuals with epidermolysis bullosa under the Medicaid program (taking into account any such treatment avoided due to such program).
(2)
An analysis of health outcomes for such individuals compared to such outcomes before such program.
(3)
Any recommendations relating to how to prevent hospitalizations relating to epidermolysis bullosa.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2026-03-09
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.

Sponsors

Rep. Greg Landsman (D) sponsors H.R. 7877, and 5 members have co-sponsored it.

Committees

H.R. 7877 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · Mar 9, 2026 · 1,636 Bills

Actions

H.R. 7877 has taken 3 actions since Mar 9, 2026, the latest on Mar 17, 2026.

ChamberAction
Mar 17, 2026
House
Sponsor introductory remarks on measure. (CR H2535)
Mar 9, 2026
House
Introduced in House
Mar 9, 2026
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.R. 7877 has not gone to a roll call.

Titles

H.R. 7877 goes by 3 titles, 1 of them short titles.

  • Shane DiGiovanna Act — Display Title
  • Shane DiGiovanna Act — Short Title(s) as Introduced
  • To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program. — Official Title as Introduced

Classification

The Congressional Research Service files H.R. 7877 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 7877’s is Health.

hr7877/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 7877, as entered in the Congressional Record.

[Congressional Record Volume 172, Number 43 (Monday, March 9, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. LANDSMAN:H.R. 7877.Congress has the power to enact this legislation pursuantto the following:United States Constitution Article 1 Section 8[Page H2477]

Source: congress.gov · legiscan.com